WuXi Biologics signs a strategic Memorandum of Understanding with the Qatar Free Zones Authority to expand into the Middle East. The collaboration will establish WuXi’s first integrated CRDMO center in the region, combining its capabilities with Qatar’s biopharmaceutical development strategy. The goal is to drive innovation, accelerate growth in Qatar’s biotechnology sector, and create a broader Middle Eastern biopharmaceutical ecosystem. WuXi Biologics is currently trading 1.26% lower at HKD 31.320 on the Hong Kong Stock Exchange.

Read more at Nasdaq: WuXi Biologics Signs MoU With Qatar Free Zones Authority To Set Up Middle East CRDMO Center